Los Angeles Capital Management
PHAT icon

Los Angeles Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Los Angeles Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Sell
24,676
-8,749
-26% -$111K ﹤0.01% 1057
2025
Q4 		$445K Buy
+33,425
New +$477K ﹤0.01% 935
2025
Q2 		– Sell
-60,056
Closed -$377K – 1431
2025
Q1 		$377K Buy
60,056
+38,986
+185% +$237K ﹤0.01% 826
2024
Q4 		$171K Buy
+21,070
New +$261K ﹤0.01% 1072

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Los Angeles Capital Management's PHAT Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Phathom Pharmaceuticals (PHAT) stake by 26% in Q1 2026, selling an estimated $111K and leaving 24,676 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

Los Angeles Capital Management first reported a position in PHAT in Q4 2024 and has held it in 4 quarters since. The position peaked at $445K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Los Angeles Capital Management held 24,676 shares of Phathom Pharmaceuticals worth $274K as of Q1 2026.
  • Los Angeles Capital Management sold 8,749 Phathom Pharmaceuticals shares in Q1 2026, an estimated $111K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1057 holding.
  • Los Angeles Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Phathom Pharmaceuticals position peaked at $445K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.